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Interruption of the enterohepatic circulation of bile acids can be 
pathophysiological feature of diseases, such as cystic fibrosis (CF), mostly via 
intestinal bile acid malabsorption. On the other hand, induction of bile acid 
malabsorption has emerged as a therapeutic option for specific conditions. 
Interruption of the enterohepatic circulation has implications beyond changes in the 
intestinal absorption of lipids an fat soluble vitamins. In this thesis we assessed 
both bile acid malabsorption in a disease state, CF, and as a possible therapy for 
hypercholesterolemia, obesity, type 2 diabetes mellitus (T2DM) and non-alcoholic 
fatty liver disease (NAFLD).   
 
Clinical assessment of bile acid homeostasis and hepatic disease in cystic fibrosis  
CF is an autosomal recessive genetic disorder resulting in dysfunction of the 
cystic fibrosis transmembrane regulator (CFTR) protein. CFTR functions as a 
transmembrane chloride transporter and its dysfunction leads to formation of 
abnormally thick, dehydrated mucus in various organs. Clinically, exocrine 
pancreas insufficiency leading to nutritional problems and pulmonary issues such 
as recurring infections and fibrosis have been the main cause of morbidity and 
mortality. Over the last 50 years, improved treatment options for CF have 
dramatically increased life expectancy from about 4 years to a currently predicted 
median survival of about 44 years (1). At this moment over 300 disease causing 
CFTR mutations have been identified (2). While most CFTR mutations are well 
known and can be categorized in genetic severity of disease, the clinical 
complications and course of the disease for individual patients is still highly 
variable. There is no good correlation between the type of CFTR gene mutation 
and specific aspects of the clinical phenotype, suggesting involvement of both 
genetic and environmental modifying factors (3). With the increase in life 
expectancy, the importance to address potential clinical problems beyond 
pulmonary and nutritional issues has increased. Complications of the hepatobiliary 
and gastrointestinal system are common, with liver disease now being the third 
leading cause of mortality in CF patients (4). Major complications, such as liver 
cirrhosis or intestinal obstruction, may overshadow less severe complications, such 
as constipation or general gastrointestinal discomfort, which, however, can still 
significantly impact quality of life (5). In chapter 2 we reviewed the liver 
involvement in cystic fibrosis (cystic fibrosis liver involvement; CFLI) and addressed 
the complex clinical approach to the pleiotropic nature of CFLI. The 
pathophysiology of CFLI is poorly understood but, especially in the case of liver 
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cirrhosis, it is a significant contributor to the CF related morbidity and mortality 
(6,7). We found that a combination of the heterogeneity of CFLI and the lack of 
consensus on the definition for CF liver disease (CFLD) or CFLI, hampers the 
design and execution of targeted diagnostics, therapies and (preclinical) studies 
(6,8). Unfortunately, preclinical studies of CFLI are also difficult, partly due to the 
fact that available animal models not consistently reflect the human 
pathophysiology (9). Another aspect of the clinical phenotype of CF is perturbed 
bile acid homeostasis which most likely affects CFLI and vice versa (10,11). 
In chapter 4 we found that bile acid malabsorption in cystic fibrosis is 
measurable in plasma via the surrogate markers fibroblast growth factor 19 
(FGF19) and 7α-hydroxy-4-cholesten-3-one (C4). FGF19 is released from the 
distal ileum upon activation of the nuclear farnesoid X receptor (FXR) by absorbed 
bile acids. C4 is an intermediate molecule in the bile acid synthesis pathway. 
Under conditions of bile acid malabsorption, plasma FGF19 levels decrease and, 
by compensatory increased bile acid synthesis, plasma C4 levels increase (12,13). 
We showed that the disruption of bile acid homeostasis correlates poorly to CFTR 
dysfunction in other organs/tissues, such as measured by sweat chloride levels, or 
pulmonary function (FEV1). This highlights the role for organ specificity and 
modifying factors in CF. It is not surprising that especially the intestine is subject to 
environmental modifiers. Gastrointestinal factors such as microbiota are directly 
affected by the environment (e.g. through differences in nutrition or antibiotic use). 
While this makes the gastrointestinal system in CF difficult to study, it is also 
attractive for potential therapies as intestinal factors may be more easily modifiable 
in comparison to targets directly related to the genetic mutation.  
 
Treatment of bile acid malabsorption and gastrointestinal complications in cystic 
fibrosis 
We showed in chapter 5 that treatment with the common laxative, polyethylene 
glycol (PEG) partially restored the interruption of the enterohepatic circulation in CF 
mice. PEG is a frequently prescribed treatment for constipation, both in CF and in 
non-CF patients. CF patients often suffer from constipation and in more severe 
cases distal intestinal obstruction syndrome (DIOS), defined as acute complete or 
incomplete faecal obstruction in the ileocaecum (14). In a cohort of pediatric CF 
patients, prevalence of constipation was 47% and this correlated to degree of fat 
malabsorption (5). The potential clinical significance of constipation and the use of 
PEG in CF patients should therefore not be underestimated. In CF mice it was 






overgrowth and intestinal inflammation improved upon PEG treatment (15). Both 
CF mice and patients display an increased intestinal permeability (16–20). In a 
recent study, chow fed PEG treated mice were shown to be protected from 
development of significant dysbiosis (more Escherichia Coli) and CF-related 
cholangiopathy in the liver compared to CF mice fed with a liquid diet high in 
medium chain triglycerides , suggesting a role for dysbiosis and intestinal 
permeability in CFLI (21). The mechanism underlying the improvements upon PEG 
treatment is not understood. PEG treatment altered microbiota and decreased 
fecal excretion of secondary bile acids in (non-CF) rats (22). It is therefore tempting 
to speculate that in the CF condition PEG may also alter the microbiota and that 
this is related to its effects on the bile acid homeostasis. Alternatively, direct 
improvements of the viscosity of the intestinal mucus layer might be involved. In 
WT mice, (high doses of) PEG significantly changed the mucus layer and 
microbiota (23).  
CF patients display aberrant intestinal microbiota compared to non-CF controls 
(24). Overt problems like intestinal dysbiosis and small intestinal bacterial 
overgrowth (SIBO) are common complications in CF. These problems in CF 
patients are complex since patients may not only be predisposed to dysbiosis due 
to consequences of the disease (changes in mucus and immune function) but also 
indirectly, as the result of frequent antibiotic use for pulmonary infections (25). 
Improving dysbiosis via probiotics (Lactobacillus reuteri, Lactobacillus rhamnosus 
GG or a mix of strains) has shown promising effects on gastrointestinal function by 
lowering fecal calprotectin levels, a marker for intestinal inflammation, and in 
decreasing the frequency of pulmonary exacerbations (26). A bi-directional 
relationship exists between bile acid homeostasis and intestinal microbiota (27). 
Changes in absolute or relative (intestinal) bile acid levels can alter the 
composition microbiota species as they can be toxic to certain species while 
providing provide others with reaction substrates. In turn, abundance of specific 
microbiota species with the ability to biotransform bile acids, changes the 
(intestinal) bile acid profile and subsequent bile acid activated receptor signaling.  
Therefore, improvement of bile acid homeostasis potentially alters microbiota but 
treatment of dysbiosis  may also affect bile acid homeostasis. Furthermore, 
changes in microbiota and bile acid homeostasis modify gastrointestinal, hepatic, 
immune and metabolic functions (27,28). Based on current literature, we 
speculated on a multitude of potential effects of bile acid malabsorption in CF on 
these functions in chapter 3 (10).  
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Apart from improving bile acid homeostasis with PEG in CF mice, we 
demonstrated in chapter 4 that ivacaftor, a CFTR potentiator, improved key 
parameters of bile acid homeostasis in CF patients with a class III gating mutation. 
The improvements did not correlate with any other measured CF related outcomes, 
including sweat chloride levels, a surrogate marker for CFTR function (in sweat 
glands). Ivacaftor treatment has also been shown to improve other gastrointestinal 
factors in CF (29). In a case report of a 6-year old CF patient, ivacaftor treatment 
reduced histologic mucus inspissation in the small intestine (30). A recent study 
showed that ivacaftor treatment in CF patients decreased intestinal inflammation 
(as measured by fecal calprotectin) and induced changes in intestinal microbiota 
potentially related to the improvements in inflammation (increase in Akkermansia 
and decrease in Enterobacteriaceae species) (31). However, the underlying 
mechanism of these gastrointestinal improvements and bile acid homeostasis in 
CF remains unexplained. Based on current literature and our observations of 
improved bile acid homeostasis upon PEG or ivacaftor treatment, bile acid 
malabsorption could either be caused by 1) an altered mucus layer, 2) changes in 
microbiota, 3) a direct effect of CFTR on ASBT function or expression, 4) a direct 
effect of CFTR on FXR activation or expression, or a combination of any of these 
factors (Fig. 1). As all these factors are modifiable (i.e. FXR agonists, probiotics), 
research into the underlying mechanism could also potentially lead to novel drug 










Figure 1. Overview of potential (in)direct effects of CFTR function on intestinal bile acid 
absorption. Lumenal BA are absorbed either actively via ASBT or passively after deconjugation over 
the membrane. Intracellularly, BA activate FXR for subsequent release of FGF15/19 into the blood. 
ASBT: apical sodium dependent bile acid transporter, BA: bile acids, FGF15/19: fibroblast growth factor 
15/19, FXR: farnesoid X receptor. 
 
The role of ASBT in intestinal cholesterol and fat absorption and the consequences 
for transintestinal cholesterol excretion (TICE) 
In chapters 6 and 7 we demonstrated that genetic inactivation of ASBT nearly 
abrogates intestinal cholesterol absorption and significantly decreases overall fat 
absorption, with the most pronounced effects on the absorption of saturated fatty 
acids. Cholesterol is disposed from the body mainly via the feces in the form of 
acidic sterols (bile acids) or neutral sterols (cholesterol and its microbial 
metabolites). The fecal source of neutral sterols is either via the diet, the bile or the 
direct excretion through a pathway known as transintestinal cholesterol excretion 
(TICE). TICE has recently become recognized as a major contributing pathway to 
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cholesterol excretion in both mice and humans (32–34). To what extent cholesterol 
excreted into the intestine via the TICE pathway is subjected to reabsorption is not 
known. In chapter 6 we used ezetimibe, an NPC1L1 inhibitor, and genetic 
inactivation of Asbt (Asbt
-/-
 mice) to investigate the contribution of cholesterol 
reabsorption to TICE. Previous data suggested that fractional cholesterol 
absorption is only partially decreased in Asbt
-/-
 mice (35). However, we found that 
intestinal cholesterol absorption in Asbt
-/-
 mice was completely abrogated, to the 
same extent as treatment with ezetimibe. Previous studies showed that ezetimibe 
increased fecal sterol excretion beyond what was expected based upon dietary 
and biliary input (36–38). This mechanism was majorly dependent on the presence 
of the cholesterol efflux transporters, ATP-binding cassette sub-family G members 
5 and 8 (ABCG5/8). ABCG5/8 mediate both cholesterol efflux from the liver into 
bile and from the intestine directly into the lumen (39). We found no difference in 
intestinal expression of Abcg5/8 upon abrogation of cholesterol absorption. We 
argue based on our data that impairment of cholesterol absorption is a main driver 
of TICE because abrogation of cholesterol absorption using two different models, 
caused a similar change in TICE flux. Our interpretation of these observations is 
that there is a continuously present Abcg5/8 mediated TICE flux that, under 
physiological conditions, is predominantly reabsorbed (38). TICE has been 
recognized as a potential target for drugs in the treatment for hypercholesterolemia 
(40). Based on our interpretation, we proposed a new model of (intestinal) 
cholesterol fluxes where intestinal excretion (i.e. TICE) minus intestinal 
(re)absorption is represented by the net transintestinal balance (Fig. 2).  This 
means TICE can be increased either by direct stimulation of involved efflux 
mechanisms and/or by inhibition of the intestinal (re)absorption. Our present 
results offer an explanation for the previously described major additional effect of 
treatment with an intestinal FXR agonist in conjunction with ezetimibe on fecal 
cholesterol excretion (41). Overexpression of Abcg5/8 was also shown to greatly 
induce biliary and intestinal cholesterol efflux (42). Therefore, we speculate that 
treatments that target both induction of TICE and inhibition of cholesterol 
(re)absorption could be very efficient for the prevention and management of 







Figure 2. Proposed model of cholesterol fluxes contributing to fecal neutral sterol excretion. The 
net transintestinal (cholesterol) balance is represented by [excretion]-[(re)absorption] and is calculated 
by subtracting biliary and dietary cholesterol input from fecal neutral sterol ouput  
 
The mechanism underlying the effects of ASBT inhibition on cholesterol and fat 
absorption is likely mediated through a significantly decreased bile acid pool that is 
insufficient to facilitate lipid absorption (35). Bile acids are necessary for the 
formation of micelles that facilitate the transport of hydrophobic compounds over 
the unstirred water layer and need to be present in a critical micellar concentration 
(43,44). This hypothesis is supported by the findings in chapter 7 that the 
absorption of hydrophobic fatty acids (long chain saturated fatty acids, SFAs) is 
particularly impaired, whereas the absorption of unsaturated fatty acids is relatively 
preserved.  
The role of ASBT inhibition in diet induced obesity  and glucose metabolism  
Modulating bile acids and their receptors has emerged as an interesting novel 
therapeutic target in the treatment of various hepatic and metabolic disorders 
(45,46). While, in chapters 3, 4 and 5 we explored bile acid malabsorption as a 
result of disease and its potential for treatment, in chapter 6, 7 and 8 we 
investigated the role of exploiting bile acid malabsorption to improve metabolic 
abnormalities. We demonstrated the potential of using ASBT inhibition to improve 
diet induced obesity, glucose metabolism and hepatic lipid accumulation.  
 
 






Figure 3. Mechanism of the beneficial effects of ASBT inhibition on metabolism and NAFLD. 
Beneficial effects of ASBT inhibition are likely mediated through a combination of altered intestinal bile 
acid levels and changes in bile acid pool size and profile leading to subsequent changes in lipid 
absorption, ceramides and FXR and TGR5 signaling. A potential role changed L-cell activation and 
microbiota might also be involved.  
ASBT: apical sodium dependent bile acid transporter, FXR: farnesoid X receptor, FGF15/19: fibroblast 
growth factor 15/19, GLP-1: glucagon like peptide-1, TGR5: Takeda G-protein coupled receptor 5  
 
Bile acid malabsorption has various beneficial effects on metabolism, and it is 
likely that changes in multiple processes contribute to these effects (Fig. 3). In 
chapters 7 and 8 we showed the potential role of decreased fatty acid absorption 
for the beneficial effects on diet induced obesity, insulin resistance and non-






acid pool composition and receptor signaling. Prevention of ileal bile acid 
reabsorption results, much like bile acid sequestration, in higher colonic bile acid 
concentrations which are expected to change subsequent receptor signaling. More 
studies exist on the role of bile acid sequestrant therapy in metabolism than for 
ASBT inhibition, from which some lessons can be learned. First generation bile 
acid sequestrants (cholestyramine, colestipol) have a greater affinity for dihydroxy 
than trihydroxy bile acids while the more recently developed colesevelam binds all 
bile acid species with high affinity, via both hydrophobic and ionic sites (47). Upon 
bile acid sequestration bile acids that are not absorbed in the colon induce 
activation of the G-protein coupled bile acid receptor 1 (GPBAR1, GPCR19 also 
known as TGR5) and promote glucagon like protein-1 (GLP-1) release (48,49). 
However, the relationship between colonic bile acid concentrations and GLP-1 
release is complex. Trabelsi et al. provided evidence that, in mice, the metabolic 
benefits of the bile acid binding sequestrant colesevelam are mediated by inhibition 
of FXR since the beneficial effects of colesevelam on glucose metabolism and 
GLP-1 disappeared upon genetic inactivation of FXR (50). However, an important 
difference between bile acid sequestrants and ASBT inhibitors is their effect on bile 
acid composition. Colesevelam in WT mice increased fecal bile acid excretion of all 
species, most notably for deoxycholic acid (DCA), while the bile acid pool size and 
biliary bile acid secretion rate remained unchanged due to compensatory synthesis 
(51). The biliary bile acid composition consisted of slightly more cholic acid (CA) 
but otherwise did not change compared to untreated WT mice. In mdr2
-/-
 mice 
colesevelam increased absolute fecal concentrations of all bile acid species but 
mostly CA and DCA, thereby increasing hydrophobicity (52). Concomitantly, the 
biliary bile acid composition shifted towards a more hydrophilic, FXR antagonistic 
profile, containing more β and ω-muricholic acid (MCA). We have consistently 
shown in chapters 6, 7 and 8 that ASBT inhibition alters the bile acid profile in bile, 
plasma and feces towards a more hydrophobic profile, containing more CA and 
DCA at the expense of β-MCA. Bile acid binding via sequestrants likely alters 
properties of bile acids, thereby interfering with passive colonic reabsorption and 
preventing the subsequent increase in DCA concentrations in the plasma and bile. 
While DCA is a potent activator of TGR5, it is also a potent activator of FXR. In 
Zucker diabetic rats, treatment with an ASBT inhibitor increased plasma GLP-1 
levels and decreased glucose levels (53). Co-treatment with an FXR agonist for 
two days did not attenuate the effects on glucose levels suggesting that, in contrast 
to the proposed mechanism of bile acid sequestrants, FXR inhibition is likely not 
involved in modulating the benefits of ASBT inhibition on glucose metabolism. How 
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changes in bile acid profile upon ASBT inhibition potentially affect FXR and TGR5 
activation and subsequent GLP-1 secretion from the intestine remains elusive. We 
found that both absolute biliary and fecal concentrations of (tauro-)β-MCA, a potent 
FXR antagonist (54), decrease upon ASBT inhibition. Compared to colesevelam 
treatment, these differences in MCA species, could mitigate effects on GLP-1 
release in mice. In humans, colesevelam increased the CA pool size at expense of 
chenodeoxycholic acid (CDCA) and DCA (55). However, these changes correlated 
poorly to improvements in metabolic parameters. It was suggested that another, 
indirectly involved mechanism might result in an increase of GLP-1 release through 
unabsorbed fatty acids activating L-cells in the more distal intestine (56).  
We and others consistently demonstrated that ASBT inhibition or genetic 
inactivation in mice reduces ileal Fxr activation and the expression of its target 
genes including Fgf15 (35,57–60). Genetic (whole body) inactivation of FXR has 
been shown to reduce diet induced weight gain and improve glucose metabolism in 
mice, while specific hepatic FXR deletion did not (61). Moreover, treatment with a 
selective intestinal FXR inhibitor improved features of diet induced obesity and 
metabolism in mice via modulating thermogenesis (62). While we did not observe a 
statistically significant difference in energy expenditure between Asbt
-/-
 and WT 
mice in calorimetric cages (chapter 7), it is still possible that a slight change 
contributed to the overall beneficial metabolic phenotype.  
As previously mentioned, a bi-directional relationship exists between bile acid 
homeostasis and microbiota (27). Changes intestinal bile acid concentrations alter 
microbiota composition. In turn, specific microbiota species biotransform bile acids 
and affect the bile acid pool composition.  Because of its profound effects on bile 
acid homeostasis, ASBT inhibition likely also induces changes in microbiota. 
However, the specific changes upon ASBT inhibitor treatment have never been 
assessed and it is even harder to establish how potential changes relate to the 
observed benefits. Colesevelam treatment in mdr2
-/-
 mice significantly altered 
intestinal microbiota, but the consequences of these changes were not explained 
(52). In turn, modulating microbiota via a probiotic mixture (VSL#3) has been 
shown to enhance intestinal bile acid deconjugation, preventing their reabsorption 
and subsequently reducing Fxr-Fgf15 signaling in mice (63).  
 
The role of ASBT inhibition in non-alcoholic fatty liver disease 
We found that ASBT inhibition consistently lowered hepatic lipid accumulation in 
mice under various of experimental and dietary conditions (chapters 7 and 8) (59). 






with steatosis eventually developing fibrosis. The stage of fibrosis severity 
correlates well with clinical outcomes and is the strongest predictor for overall and 
liver-related mortality (64–66). Therefore, prevention of fibrosis has clinically 
become the most important target for NAFLD therapies. Unfortunately, it is not 
known what determines whether steatosis will develop into fibrosis. It likely 
involves a complex of genetic and environmental factors (67). The presence of 
non-alcoholic steatohepatitis (NASH) was suggested as an important factor 
increasing the risk of fibrosis but recent studies suggest it to be of limited 
prognostic value (68,69).  
Mice do not readily develop fibrosis on a western type or high fat diet (HFD) 
unless fed for a considerably long time or combined with another hepatic injury 
(70). This fact makes preclinical studies on NAFLD – fibrosis progression difficult, 
although not impossible.  In chapter 8 we used a choline deficient L-amino acid 
defined (CDAA) diet, shown to induce steatosis and subsequent fibrosis after 22 
weeks in mice, to explore the effects of ASBT inhibition on development of NAFLD 
related fibrosis (71,72). We found that in the context of choline deficiency, some of 
the previously consistent effects of ASBT inhibition including reduction of intestinal 
lipid absorption and prevention of hepatic triglyceride accumulation (chapters 6 
and 7) were attenuated. In addition, ASBT inhibitor treatment did not prevent the 
development of hepatic fibrosis. The mechanism underlying these effects remains 
unexplained. Furthermore, while intestinal fat absorption is likely an important 
contributor to the metabolic and especially hepatic benefits mediated by ASBT 
inhibition or inactivation, combined consideration of chapters 7 and 8 demonstrate 
that other factors are involved as well (Fig. 3). It would be interesting to see the 
effects of ASBT inhibition in different, recently developed, NAFLD mouse models 
that better mimic the human pathology (73,74). 
As there are many similarities between the risk factors and pathogenesis of 
obesity and insulin resistance and NAFLD, the discussed changes upon ASBT 
inhibition that reduce diet induced obesity and metabolic abnormalities are likely to 
also affect NAFLD development (Fig. 2). However, both we, in chapter 8, and Rao 
et al. showed profound effects on hepatic lipid accumulation without similar effects 
on bodyweight or glucose homeostasis, suggesting some degree of liver specific 
effects of ASBT inhibition (59).  
Lower intestinal Fxr activation and subsequent Fgf15 expression upon ASBT 
inhibition could be involved in modulating the effects on hepatic steatosis. In line 
with the observations on diet induced obesity, specific inactivation of intestinal Fxr 
in mice reduced HFD induced NAFLD development due to a reduction in ceramide 
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production (75). However, genetic inactivation of Fgf15 in mice promoted 
bodyweight gain and hepatic steatosis in a HFD model (76). Conversely, in another 
study using long-term HFD feeding to induce NASH, steatosis, inflammation and 
bodyweight gain were not affected, while fibrosis was reduced in Fgf15
-/-
 mice (77). 
Hepatic fibrosis was also reduced in Fgf15
-/-
 mice using carbon tetrachloride 
injections to induce hepatic fibrosis (78). How the absence of Fgf15 reduced 
fibrogenesis in these studies remained unexplained. Fxr
-/-
 mice on a methionine 
choline deficient (MCD) diet, showed decreased steatosis compared to controls but 
increased NASH and fibrosis (79). This was explained by increased hepatic bile 
acid concentrations, which is not observed upon ASBT inhibition, that resulted in 
hepatotoxicity. Another potential explanation for reduced hepatic lipid 
accumulation, proposed by Rao et al., involves the change in hepatic bile acid 
composition to contain more FXR agonistic species, changing hepatic specific FXR 
signaling and subsequently affecting mainly lipogenesis (59). Both whole body and 
hepatic specific Fxr
-/-
 mice display increased hepatic triglyceride and cholesterol 
accumulation even on a low-fat control diet (80,81). Hepatic transcriptome data of 
HFD fed mice treated for 16 weeks with an ASBT inhibitor showed most 
pronounced changes in genes involved in protein modification and lipid, fatty acid, 
and steroid metabolism (59). In general, FXR agonists have shown potential 
benefits in NAFLD and NASH (82). However, most of the studied FXR agonists 
concomitantly activate both hepatic and intestinal FXR and therefore the (long-
term) specific effects of altering increasing hepatic FXR signaling (while decreasing 












Intestinal bile acid malabsorption induces a pleiotropy of changes that, 
depending on the underlying conditions, can have either positive or negative 
consequences for health. CF is a monogenetic disease that results in a complex 
metabolic phenotype, illustrated by the highly variable presentation of liver disease. 
We showed that bile acid malabsorption is an important feature of CF. Treatment 
by directly targeting CFTR or by using a laxative improved bile acid homeostasis. 
Our data indicate that these treatments could affect the bile acid metabolism 
related gastrointestinal, metabolic and hepatic features of CF. Future studies are 
necessary to establish the mechanism underlying the bile acid malabsorption in CF 
and the potential clinical benefits of modulating bile acid homeostasis to improve 
other complications.  
We demonstrated that bile acid malabsorption due to inactivation of ASBT 
abrogates cholesterol absorption, providing novel insights into the role of 
cholesterol absorption in the intestinal cholesterol fluxes, including TICE. We 
further found that the benefits on metabolic homeostasis and NAFLD observed 
upon ASBT inhibition are partly mediated through a reduction of intestinal fatty acid 
absorption. Initial studies of ASBT inhibitors showed promising results in primary 
biliary cirrhosis and T2DM patients, but further application has been limited by a 
high frequency of gastrointestinal side-effects, mainly diarrhea (83–85). However, 
SHP626 (formerly LUM002) is currently in phase 2 clinical trials for treatment of 
NASH (ClinicalTrials.gov Identifier: NCT02787304). In the future, development of 
novel ASBT inhibitors and possible combined treatments with bile acid 
sequestrants might improve their tolerability.  
 
Taken together, this thesis highlighted the prominent role of bile acid 
homeostasis in gastrointestinal, metabolic and hepatic function. Modulating the 
enterohepatic circulation of bile acids either directly or indirectly is a powerful tool 
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